Conjugated compounds comprising cysteine-engineered antibodies
US10744204B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 10, 2015 |
| Grant date | Aug 18, 2020 |
| Priority date | — |
| Expiry date | May 16, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure provides conjugate compounds comprising antibodies and fragments thereof engineered with one or more reactive cysteine residues and more specifically to conjugate compounds with therapeutic or diagnostic applications. The conjugate compounds comprise cysteine-engineered antibodies or fragments thereof conjugated, for example, with chemotherapeutic drugs, toxins, and detection labels such as radionuclides or fluorophores. The disclosure also provides methods of using the disclosed conjugate compounds for in vitro, in situ, ex vivo, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.